Prognostic value of oral candidosis and hairy leukoplakia in 111 Mexican HIV-infected patients.
A follow-up study was carried out to evaluate the prognostic value of hairy leukoplakia (HL) and oral candidosis (OC) in a cohort of 111 asymptomatic Mexican HIV infected patients. Oral exams were performed at baseline and every 6 months, from September 1989 to March 1994. Chi-square contingency table test, the Kruskall-Wallis one-way analysis of variance, the Kaplan-Meier product-limit method and the log rank test were used for the analysis. Univariate and multivariate Cox's proportional hazards analysis were also performed. Fifty-four patients (51%) progressed to AIDS (initially 36 CDC-II and 18 CDC-III). Individuals with HL and/or OC, showed faster development to AIDS than subjects without lesions or other HIV-related manifestations (P = 0.008). The presence of OC, HL or both always remained significant despite adjustment for total lymphocytes, CDC stage, zidovudine therapy or its combinations. Oral lesions in HIV infection may be regarded with other clinical and laboratory studies as markers of HIV disease progression and as indicators to begin antiretroviral treatment.
Ramírez-Amador
V A
VA
Department of Health Care, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico.
Esquivel-Pedraza
L
L
Ponce de León
S
S
Ponce de León
S
S
D017088:AIDS-Related Opportunistic Infections / Q000473:pathology*; D000163:Acquired Immunodeficiency Syndrome / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D019380:Anti-HIV Agents / Q000627:therapeutic use; D002180:Candidiasis, Oral / Q000473:pathology*; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000145:classification / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D017733:Leukoplakia, Hairy / Q000473:pathology*; D016014:Linear Models; D018655:Lymphocyte Count; D008297:Male; D008800:Mexico; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D015215:Zidovudine